Publikationen in Zusammenarbeit mit Forschern von Ulsan University Hospital (2)

2020

  1. Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: Subgroup analysis of CASTOR based on cytogenetic risk

    Journal of Hematology and Oncology, Vol. 13, Núm. 1

2018

  1. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of CASTOR

    Haematologica, Vol. 103, Núm. 12, pp. 2079-2087